top of page
Eli Lilly Just Bought AtaiBeckley for $3.8 Billion. The Market's Cheering. We're Not So Sure.
Big Pharma doesn't chase fringe science. Not unless the data forces its hand. That's what makes this week's news notable. On July 16, 2026, Eli Lilly (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley Inc. (Nasdaq: ATAI) — the psychedelic-medicine company formed less than a year ago through the merger of Germany's atai Life Sciences and the UK's Beckley Psytech. It's Lilly's first move into psychedelics, and it comes on the heels of a broader acquisition spre
Rebellionaire Staff
Jul 163 min read
bottom of page